Our observations therefore point to ALAL-1 as a possible target for lung cancer therapies, suggesting that the in vivo inhibition of ALAL-1 could have a “double-hit” anti-tumor effect: on one hand, by decreasing the autonomous capacity of cells to survive and proliferate and, on the other hand, by promoting immune infiltration and response against the tumor. The gene discussed is IKBKB-DT; the disease is lung cancer.